

available at [www.sciencedirect.com](http://www.sciencedirect.com)journal homepage: [www.elsevier.com/locate/biochempharm](http://www.elsevier.com/locate/biochempharm)

# Histamine H<sub>3</sub> and dopamine D<sub>2</sub> receptor-mediated [<sup>35</sup>S]GTPγ[S] binding in rat striatum: Evidence for additive effects but lack of interactions

Marie Humbert-Claude, Séverine Morisset, Florence Gbahou, Jean-Michel Arrang\*

INSERM, Unité de Neurobiologie et Pharmacologie Moléculaire (U573), Centre Paul Broca, 75014 Paris, France

## ARTICLE INFO

### Article history:

Received 4 October 2006

Accepted 3 January 2007

### Keywords:

Histamine

H<sub>3</sub> receptor

D<sub>2</sub> receptor

Constitutive activity

G<sub>i/o</sub> protein

[<sup>35</sup>S]GTPγS

## ABSTRACT

The interactions in the rat striatum between H<sub>3</sub> receptors (H<sub>3</sub>Rs) and D<sub>2</sub> receptors (D<sub>2</sub>Rs) were investigated with the [<sup>35</sup>S]GTPγ[S] binding assay. The H<sub>3</sub>R agonist (R)α-methylhistamine increased [<sup>35</sup>S]GTPγ[S] binding to striatal membranes with an EC<sub>50</sub> = 14 ± 5 nM and a maximal effect of +19 ± 1%. This effect was inhibited by the H<sub>3</sub>R antagonist ciproxifan with a K<sub>i</sub> = 1.0 ± 0.3 nM. The D<sub>2</sub>R agonist quinpirole increased [<sup>35</sup>S]GTPγ[S] binding to the same membranes with an EC<sub>50</sub> = 1.5 ± 0.5 μM and a maximal effect of +28 ± 2%. Its effect was blocked by haloperidol with a K<sub>i</sub> = 0.3 ± 0.1 nM. The maximal effects of the H<sub>3</sub>R and D<sub>2</sub>R agonists were additive (+46 ± 3%). However, D<sub>2</sub>R ligands did not modify the effects of H<sub>3</sub>R ligands and vice versa. Ciproxifan behaved as an H<sub>3</sub>R inverse agonist and decreased [<sup>35</sup>S]GTPγ[S] binding. Haloperidol had no effect and did not change the inverse agonist effect of ciproxifan. Administrations for 10 days of ciproxifan (1.5 mg/kg/day) or haloperidol (0.5 mg/kg/day) did not change the effects of quinpirole and (R)α-methylhistamine, respectively. These data suggest that striatal H<sub>3</sub>Rs and D<sub>2</sub>Rs do not interact through their coupling to G-proteins. However, a hyperactivity of histaminergic and dopaminergic neurons being observed in schizophrenia, the additive activations of H<sub>3</sub>Rs and D<sub>2</sub>Rs suggest that they cooperate to generate some schizophrenic symptoms. Such a postsynaptic mechanism may underlie the antipsychotic-like effects of H<sub>3</sub>R inverse agonists and supports their therapeutic interest, alone or as adjunctive treatment with neuroleptics.

© 2007 Elsevier Inc. All rights reserved.

## 1. Introduction

The effects of histamine in the brain are mediated by three histamine receptor subtypes (H<sub>1</sub>, H<sub>2</sub> and H<sub>3</sub>), which have been defined by means of functional assays followed by design of selective agonists and antagonists and, more recently, cloning of their genes [1,2]. All three belong to the superfamily of G-protein-coupled receptors with seven transmembrane domains. We initially detected and identified the H<sub>3</sub> receptor (H<sub>3</sub>R) by traditional pharmacological approaches as an auto-

receptor controlling histamine synthesis and release in the rat and human brain [3–5]. The inhibition of adenylate cyclase and activation of phospholipase A<sub>2</sub> mediated by the recombinant receptor in various cell lines [6–9], as well as the sensitivity of responses mediated by H<sub>3</sub>Rs in the brain [10,11], indicated that the H<sub>3</sub>R is coupled to G<sub>i/o</sub> proteins.

The inhibition mediated by H<sub>3</sub> autoreceptors is now well established as a major control mechanism for the activity and functions of histaminergic neurons under physiological conditions [4,12]. H<sub>3</sub>R antagonists/inverse agonists enhance

\* Corresponding author at: Unité de Neurobiologie et Pharmacologie Moléculaire (U573), Centre Paul Broca de l'INSERM, 2 ter rue d'Alésia, 75014 Paris, France. Tel.: +33 1 40 78 92 84; fax: +33 1 45 80 72 93.

E-mail address: [arrang@broca.inserm.fr](mailto:arrang@broca.inserm.fr) (J.-M. Arrang).

0006-2952/\$ – see front matter © 2007 Elsevier Inc. All rights reserved.

doi:10.1016/j.bcp.2007.01.006

cerebral histamine turnover and release *in vivo*, indicating that autoreceptors are tonically activated [2] and their intensive use during the recent years has considerably clarified the functional roles of histaminergic neurons. Behavioural studies using imidazole or non-imidazole H<sub>3</sub>R antagonists/inverse agonists have confirmed the role played by endogenous neuronal histamine in modulation of wakefulness [13], cognition and attention [14], food intake [15] and seizures [16].

More recently, several behavioural studies also support antipsychotic-like properties of H<sub>3</sub>R antagonists/inverse agonists [17]. The locomotor activation elicited in rodent by dopaminergic agonists and the NMDA-receptor antagonist MK-801 is attenuated by standard and more recent H<sub>3</sub>R antagonists/inverse agonists [18–21] (see Ligneau et al. 2007). Also stereotypies induced in mice by methamphetamine and apomorphine are significantly decreased by ciproxifan [22] as well as by the non-imidazole inverse agonist BF2.649 [23] (see Ligneau et al. 2007). Consistent with these findings, the effect of methamphetamine on locomotor activity and stereotypic behaviour was less pronounced in H<sub>3</sub>R knockout mice [24]. H<sub>3</sub>R antagonists/inverse agonists also improve sensorimotor gating deficits, which are cardinal signs of schizophrenia, such as those which occur naturally in DBA/2 mice, or which are induced in Swiss mice by apomorphine, as shown by the increase that they induce in prepulse inhibition of startle and N40 auditory-evoked-response [20,25] (see Ligneau et al. 2007).

The neurochemical mechanisms underlying these antipsychotic-like effects induced by H<sub>3</sub>R blockade remain unknown. The enhancement of histamine neuron activity induced by H<sub>3</sub>R antagonists/inverse agonists may be involved inasmuch as histidine loads or inhibitors of histamine catabolism have also been reported to reduce methamphetamine-induced stereotypies [26,27]. However, high H<sub>3</sub>R densities are present on many perikarya and/or dendrites of intrinsic neurons in the cerebral cortex, striatal complex and limbic areas [28,29].

In the striatum, the dense and homogeneous distribution of H<sub>3</sub>Rs in the caudate-putamen and nucleus accumbens as well as double labelling experiments indicate that postsynaptic H<sub>3</sub>Rs are coexpressed with D<sub>1</sub> or D<sub>2</sub> receptors [28,29]. H<sub>3</sub>R activation inhibits D<sub>1</sub>-receptor-mediated cAMP formation in the rat striatum [30] and the expression of H<sub>3</sub>Rs is influenced by endogenous activation of D<sub>1</sub> receptors [31]. The existence of putative direct interactions between postsynaptic H<sub>3</sub>Rs and D<sub>2</sub>Rs remains unclear. Complex and/or controversial neurochemical and behavioural interactions have been reported between H<sub>3</sub>R antagonists/inverse agonists and neuroleptics. We recently found that the imidazole derivative ciproxifan potentiated the enkephalin, neurotensin and c-fos expression induced in rat caudate-putamen and nucleus accumbens by haloperidol [29]. In contrast, thioperamide, another imidazole compound, has been found to decrease haloperidol-induced c-fos expression in the rat dorsolateral striatum but not in the nucleus accumbens [32]. Ciproxifan and thioperamide potentiated haloperidol-induced catalepsy in the rat [29,33] but not in the mouse [34]. Although it was totally suppressed by co-administration of (R) $\alpha$ -methylhistamine [29], the potentiation of catalepsy induced by ciproxifan in the rat, was suggested to result at least partially from an inhibition of cytochrome P450

enzymes by imidazole derivatives [35] and two non-imidazole H<sub>3</sub>R antagonists/inverse agonists tended to attenuate risperidone-induced catalepsy [33].

Consistent with an involvement of histaminergic systems in schizophrenia, the existence of a hyperactivity of histamine neurons has been reported not only in several animal models of the disease [19,21,36], but also in schizophrenic patients [37]. These findings indicate that hyperactivity of dopaminergic transmission is associated with an enhanced activity of histaminergic neurons in the disease. Therefore, an enhanced activation of postsynaptic H<sub>3</sub>Rs and D<sub>2</sub>Rs present in the striatal complex is expected to occur in schizophrenia. In the present study, we have further investigated the putative interactions between striatal H<sub>3</sub>Rs and D<sub>2</sub>Rs by using the [<sup>35</sup>S]GTP $\gamma$ [S] binding assay applied to rat striatal membranes, a functional test system previously shown to be activated by both receptors [38,39].

---

## 2. Methods

### 2.1. Animals

Male adult Wistar rats (160–200 g, Janvier, France) were housed in a quiet room under a 12-h light/dark cycle (with lights on from 7 p.m.), with food and water available *ad libitum*. Animals were killed by decapitation and the brain removed and dissected out on a refrigerated plate.

### 2.2. [<sup>35</sup>S]GTP $\gamma$ [S] binding assay

Brain tissues from rats were homogenized with a Polytron in ice-cold buffer (Tris-HCl 50 mM, pH 7.4). Homogenates were centrifuged twice at 20,000  $\times$  g for 10 min and the final pellet was resuspended in 50 volumes of buffer. Membranes (20–50  $\mu$ g) were pretreated with adenosine deaminase (ADA, 1 U/ml), and incubated for 60 mn at 25 °C with 0.1 nM [<sup>35</sup>S]GTP $\gamma$ [S] and, when required, the various drugs tested, in 1 ml of assay buffer (50 mM Tris-HCl, 50 mM NaCl, 5 mM MgCl<sub>2</sub>, 10  $\mu$ M GDP, 0.02% BSA, pH 7.4). The non-specific binding was determined using non-labelled GTP $\gamma$ S (10  $\mu$ M). Incubations were stopped by rapid filtration under vacuum through Whatman GF/B filters. Filters were washed twice with 4 ml ice-cold water and the radioactivity retained on the filters was measured by liquid scintillation spectrometry.

### 2.3. [<sup>3</sup>H]histamine binding assay

Brain tissues from rats were homogenized with a Polytron in ice-cold buffer (Na<sub>2</sub>HPO<sub>4</sub>/KH<sub>2</sub>PO<sub>4</sub> 50 mM, pH 7.5). Homogenates were centrifuged at 300  $\times$  g for 5 min. The supernatants were centrifuged at 12,000  $\times$  g for 30 min and the final pellet was resuspended in binding buffer. Aliquots of the membrane suspension (200–300  $\mu$ g) were incubated for 60 mn at 25 °C with [<sup>3</sup>H]histamine (20 nM, 1 ml final volume). The non-specific binding was determined using imetit (1  $\mu$ M). Incubations were stopped by rapid filtration under vacuum through Whatman GF/B filters. Filters were washed twice with 4 ml ice-cold buffer and the radioactivity retained on the filters was measured by liquid scintillation spectrometry.

Download English Version:

<https://daneshyari.com/en/article/2514721>

Download Persian Version:

<https://daneshyari.com/article/2514721>

[Daneshyari.com](https://daneshyari.com)